Evolução da hemovigilância no Brasil: novas perspectivas de atuação do farmacêutico

Abstract

Introduction: Transfusion therapy is indicated to maintain and reestablish homeostasis. As in administration of drugs or pharmaceuticals, there is a risk of complications related to organism-substance interaction despite the adoption of preventive measures. Recognition of the risks’ dimensions associated with transfusion therapy requires qualified regulatory action by the State and the technical team qualified for adequate monitoring. Therefore, a pharmaceutical practice was contemplated by the Resolution of the Federal Council of Pharmacy (CFF) Nº 617/2015, a qualification clinical assignments for the pharmacist in Hemotherapy. Objective: This paper proposes to carry out a systematic review of the literature on the pharmaceutical performance in Hemovigilance, discussing its new attributions. Material and methods: A review of the MEDLINE / PUBMED, SCIENCE DIRECT, LILACS and SCIELO databases was carried out in 2001 and 2018 in English, Spanish and Portuguese. Results: After the reading was possible to verify the necessity of reorientation in the pharmaceutical’s scope practices in the hemotherapy area. It is necessary to organize the "teaching-management-work" trinomial to benefit users of health systems. In addition, joint discussion among professional councils is important in establishing limits of practice and understanding of shared responsibility. Final considerations: This review reintroduces that pharmacist is the professional who promotes safety in patient care in transfusion therapy.